Phenobarbital (All indications)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10172
R37171
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 2.51 [0.14;44.28] C
excluded (control group)
0/80   7/2,997 7 80
ref
S10042
R36307
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 3.49 [0.22;56.34] C 0/80   3,371/1,875,733 3,371 80
ref
S9151
R31458
Tomson (Phenobarbital), 2018 Hypospadias at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.43 [0.17;11.89] C 1/294   6/2,514 7 294
ref
S9107
R31282
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 Hypospadias 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Controls: mixed indications 23.72 [0.96;584.27] C 1/199   0/1,562 1 199
ref
S9124
R31347
Bànhidy (Phenobarbital), 2011 Hypospadias throughout pregnancy case control unexposed, sick Adjustment: No Matched 3.80 [0.06;243.53] C 0/   3/13 3 0
ref
S9101
R31185
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 Hypospadias throughout pregnancy prospective cohort unexposed, disease free excluded Adjustment: No Matched 17.57 [0.30;1024.08] C
excluded (control group)
0/4   0/62 0 4
ref
S9102
R31214
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Hypospadias throughout pregnancy prospective cohort unexposed, sick Adjustment: No 2.14 [0.03;131.94] C 0/4   0/8 0 4
ref
S9172
R31576
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 Hypospadias throughout pregnancy prospective cohort unexposed, disease free excluded Adjustment: No Matched 4.74 [0.09;251.42] C
excluded (control group)
0/12   0/55 0 12
ref
S9173
R31601
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 Hypospadias throughout pregnancy prospective cohort unexposed, sick Adjustment: No 1.87 [0.03;100.54] C 0/12   0/22 0 12
ref
Total 6 studies 3.10 [0.88;10.93] 3,382 589
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019Blotière, 2019 1 3.49[0.22; 56.34]3,3718021%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Tomson (Phenobarbital), 2018Tomson, 2018 2 1.43[0.17; 11.89]729435%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012Hernández-Díaz, 2012 3 23.72[0.96; 584.27]119915%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Bànhidy (Phenobarbital), 2011Bànhidy, 2011 4 3.80[0.06; 243.53]3-9%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate D'Souza (Phenobarbital) (Controls unexposed, sick), 1991D'Souza, 1991 5 2.14[0.03; 131.94]049%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991Van der Pol, 1991 6 1.87[0.03; 100.54]01210%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (6 studies) I2 = 0% 3.10[0.88; 10.93]3,3825890.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital; 3: Phenobarbital) (Controls exposed to Lamotrigine, sick; 4: Phenobarbital; 5: Phenobarbital) (Controls unexposed, sick; 6: Phenobarbital) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.03[0.81; 11.39]3,3795890%NABlotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 Tomson (Phenobarbital), 2018 Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 5 case control studiescase control studies 3.80[0.06; 243.53]3- -NABànhidy (Phenobarbital), 2011 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 3.49[0.22; 56.34]3,37180 -NABlotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sickunexposed, sick 2.46[0.23; 25.99]3160%NABànhidy (Phenobarbital), 2011 D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 3 exposed to other treatment, sickexposed to other treatment, sick 4.45[0.30; 66.56]849351%NATomson (Phenobarbital), 2018 Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 2 Tags Adjustment   - No  - No 3.10[0.88; 10.93]3,3825890%NABlotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 Tomson (Phenobarbital), 2018 Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 Bànhidy (Phenobarbital), 2011 D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 6 Controls   - mixed indications  - mixed indications 23.72[0.96; 584.27]1199 -NAHernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 1 MatchedMatched 3.80[0.06; 243.53]3- -NABànhidy (Phenobarbital), 2011 1 All studiesAll studies 3.10[0.88; 10.93]3,3825890%NABlotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 Tomson (Phenobarbital), 2018 Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 Bànhidy (Phenobarbital), 2011 D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 60.550.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-5.06.12.5470.000Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019Tomson (Phenobarbital), 2018Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012Bànhidy (Phenobarbital), 2011D'Souza (Phenobarbital) (Controls unexposed, sick), 1991Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991

Asymetry test p-value = 0.5492 (by Egger's regression)

slope=0.0206 (1.7570); intercept=0.7284 (1.1148); t=0.6534; p=0.5492

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9101, 9172, 10172

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.55[0.76; 40.46]3,371960%NABlotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 3 unexposed, sick controlsunexposed, sick controls 2.46[0.23; 25.99]3160%NABànhidy (Phenobarbital), 2011 D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.15[0.67; 14.73]155734%NABlotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Tomson (Phenobarbital), 2018 Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 30.510.01.0